Risk of a first‐ever acute myocardial infarction and all‐cause mortality with sulphonylurea treatment: A population‐based cohort study. Issue 4 (27th December 2017)

• Record Type: Journal Article
• Authors: van Dalem, Judith; Brouwers, Martijn C. G. J.; Stehouwer, Coen D. A.; Krings, André; Klungel, Olaf H.; Driessen, Johanna H. M.; de Vries, Frank; Burden, Andrea M.
• Is Part Of: Diabetes, obesity & metabolism. Volume 20:Issue 4(2018)
• Page Start: 1056
• Page End: 1060
• Publication Date: 2017-12-27
• Subjects: acute myocardial infarction -- all‐cause mortality -- sulphonylureas -- type 2 diabetes mellitus; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.13168
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : We investigated the association between the current use of individual sulphonylureas and the risk of a first‐ever acute myocardial infarction (AMI) and all‐cause mortality, in a population‐based cohort study, using primary care data from the Clinical Practice Research Datalink database (2004‐2012). New users ( N = 121 869), aged ≥18 years, with at least one prescription for a non‐insulin antidiabetic agent were included. The first prescription defined start of follow‐up. Time‐dependent Cox proportional hazard models were used to estimate the risk of a first‐ever AMI and all‐cause mortality associated with the use of individual sulphonylureas, and other non‐insulin glucose‐lowering drugs. No differences in risk of a first‐ever AMI (adjusted hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.70‐1.50) or all‐cause mortality (adjusted HR 0.97, 95% CI 0.80‐1.17) were observed when comparing gliclazide use with non‐gliclazide sulphonylurea use. Similar results were found for each individual sulphonylurea. As evidence is accumulating that gliclazide is no safer than other sulphonylureas, current guidelines suggesting superiority should be carefully evaluated.